Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 4

CATABASI Form 4 July 21, 201	S PHARMACE	UTICALS	INC						
FORN Check the if no long subject to Section 1 Form 4 of Form 5 obligation may come <i>See</i> Instra 1(b).	MENT OI rsuant to S (a) of the I	Wa F CHAN Section 1 Public U	NGES IN SECUR	D.C. 20 BENEF SITIES e Securit ding Con	E COMMISSION WNERSHIP OF ange Act of 1934, t of 1935 or Sectio 1940	OMB Number: Expires: Estimated burden hou response	irs per		
 (Print or Type Responses) 1. Name and Address of Reporting Person <u>*</u> Milne Jill C. 			2. Issuer Name and Ticker or Trading Symbol CATABASIS PHARMACEUTICALS INC [CATB]				5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X_ Director 10% Owner		
ONE, KEN				of Earliest Tr Day/Year) 2015	ransaction		X Officer (giv below) Pre	e title Oth below) sident and CEC	
			4. If Amendment, Date Original Filed(Month/Day/Year)			 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting 			
(City)	(State)	(Zip)	Tab	la I Non I	Dorivativa	Socurities	Person Acquired, Disposed o	f or Bonoficio	lly Ownod
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	e 2A. Deem Execution any (Month/Da	ed Date, if ay/Year)	3. Transaction Code (Instr. 8) Code V	4. Securit nAcquired Disposed (Instr. 3, 4 Amount	(A) or of (D) 4 and 5) (A) or (D) Price	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect
Reminder: Rep	oort on a separate lin	e for each cl	ass of sec	urities benef	Perso	ns who re	or indirectly. spond to the collect stained in this form		SEC 1474 (9-02)

information contained in this form are no required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of 2 3. Transaction Date 3A. Deemed 5. Number of 6. Date Exercisable and 7. Title and Amount of 4. Derivative Conversion (Month/Day/Year) Execution Date, if TransactionDerivative Expiration Date **Underlying Securities** (Month/Day/Year) (Instr. 3 and 4) Security or Exercise any Code Securities (Instr. 3) Price of (Month/Day/Year) (Instr. 8) Acquired (A) or Derivative Disposed of (D) Security (Instr. 3, 4, and 5) Amount or Date Expiration Title Number of Exercisable Date (D) Code V Shares (A) Stock Option Common (1) 07/16/2025 \$ 14.05 07/17/2015 160,000 160,000 Α (right to Stock buy)

Edgar Filing: CATABASIS PHARMACEUTICALS INC - Form 4

Reporting Owners

Reporting Owner Name / Address	Relationships					
	Director	10% Owner	Officer	Other		
Milne Jill C. C/O CATABASIS PHARMACEUTICALS, INC. ONE KENDALL SQUARE BLDG. 1400E, SUITE B14202 CAMBRIDGE, MA 02139	Х		President and CEO			
Claura du ura a						

Signatures

/s/ Jill C. Milne 07/21/2015

**Signature of Reporting Person

Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) This option was granted on July 17, 2015 and vests over four years, with 25% of the shares vesting on the first anniversary of July 8, 2015 and the remainder vesting over the ensuing three years at a rate of 2.0833% per month.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.